Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis
Launched by BEIJING 302 HOSPITAL · Apr 26, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to detect high-risk varices, which are swollen veins in the esophagus that can occur in people with liver cirrhosis. The goal is to see if a device called iLivTouch can help identify these dangerous varices more effectively, following guidelines set by the Baveno VI group. Researchers are currently looking for participants aged 18 to 75 who have been diagnosed with liver cirrhosis. To join, participants must have undergone an examination called esophagogastroduodenoscopy within the last three months and not have experienced any serious liver-related complications during that time.
If you or a family member joins the study, you can expect to have your liver health monitored using the iLivTouch device, alongside the traditional endoscopy. It's important to note that certain conditions may exclude potential participants, such as severe liver complications, recent surgeries, or specific medications. This trial aims to improve the way doctors can screen for high-risk varices, which could ultimately help prevent serious health issues for patients with liver cirrhosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-75;
- • 2. Patients with liver cirrhosis diagnosed by clinical or imaging diagnosis;
- • 3. The interval of iLivTouch and esophagogastroduodenoscopy is no more than 3 months;
- Exclusion Criteria:
- • 1. the interval between esophagogastroduodenoscopy and iLivTouch is more than 3 months;
- • 2. any decompensation events (ascites, hepatic encephalopathy or gastroesophageal variceal bleeding) during endoscopy or iLivTouch examination, or during the interval between them;
- • 3. currently taking nonselective beta blocker/ antiplatelet / anticoagulant drugs;
- • 4. hepatocellular carcinoma;
- • 5. after transjugular intrahepatic portosystemic shunt surgery;
- • 6. after liver transplantation.
- • 7. portal-spleen-mesenteric venous thrombosis;
- • 8. patients with splenectomy;
- • 9. BMI ≥ 30;
- • 10. patients with acute active hepatitis or patients with cholestatic hepatitis;
- • 11. IQR/median of liver stiffness measurement \> 30%.
About Beijing 302 Hospital
Beijing 302 Hospital is a leading medical institution in China, renowned for its advanced clinical research and comprehensive healthcare services. As a sponsor of clinical trials, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and innovation. With a multidisciplinary team of experienced researchers and healthcare professionals, Beijing 302 Hospital focuses on a wide range of therapeutic areas, employing state-of-the-art facilities and methodologies to ensure the highest standards of trial integrity and patient safety. The hospital's dedication to ethical practices and collaboration fosters an environment conducive to groundbreaking research and the development of new treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Fu junliang
Principal Investigator
the Fifth Medical Center, Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported